ArticleFrontiers in immunology2025
Advancing breast cancer biomarkers: a centromere-related gene signature integrated with single-cell analysis for prognostic prediction.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative machine learning and multi-omics identify a centromere gene signature and validate B3GALT4 as a tumor suppressor in osteosarcoma.Journal of bone oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer (BC) is the most common malignancy among women and shows significant heterogeneity in its prognosis. Among the subtypes, triple-negative breast cancer (TNBC) has the poorest prognosis. Despite advancements in molecular stratification tools, such as Oncotype DX and MammaPrint, prognostic models based on chromosomal instability are still insufficient. The centromere protein (CENP) family, which plays a crucial role in maintaining genomic stability, is associated with tumor progression due to aberrant expression. Methods: In this study, we integrated multi-omics data, including RNA transcriptomic profiles and single-cell RNA sequencing, to identify gene modules linked to CENPA using weighted gene co-expression network analysis (WGCNA). We developed a prognostic model employing Cox regression and the LASSO algorithm. Validation was performed on independent cohorts, and the model's performance was tested by stratifying patients into high- and low-risk groups based on their five-year survival rates (p < 0.001). Results: The prognostic model effectively identified high- and low-risk patient groups, with the high-risk group showing significantly reduced five-year survival. Single-cell analysis revealed that CENPA-high subpopulations were enriched in proliferative tumor cells and were associated with an immunosuppressive tumor microenvironment. Conclusion: This study is the first to establish a CENP-based prognostic model for BC, offering novel biomarkers and potential therapeutic targets for personalized treatment. Additionally, the biological function of the key molecule MMP1 was validated through both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.